



Tumor Microenvironment and Exacerbation Mechanism in Multiple Myeloma

Guest Editor:

Prof. Dr. Hideto Tamura

1. Division of Diabetes,
Endocrinology and Hematology,
Department of Internal Medicine,
Dokkyo Medical University
Saitama Medical Center,
Minamikoshigaya, Koshigaya-shi
343-8555, Saitama, Japan
2. Division of Hematology,
Department of Medicine, Nippon
Medical School, 1-1-5 Sendagi,
Bunkyo-ku, Tokyo 113-0086,
Japan

Deadline for manuscript
submissions:
closed (28 February 2021)

Message from the Guest Editor

Dear Colleagues,

Multiple myeloma (MM) is a hematologic malignancy characterized by the clonal proliferation of plasma cells with M-protein production. Novel agents have prolonged survival in MM patients, although the disease remains incurable in the majority. Thus, new strategies are needed for the treatment of refractory MM patients and to seek a cure. To develop new treatments, it is crucial to elucidate the precise mechanisms of tumor growth and exacerbation in the myeloma microenvironment. The focus of this Special Issue is therefore on the tumor microenvironment and exacerbation mechanisms, i.e., drug resistance, proliferative signaling, immune evasion, etc., involved in aggressive disease behavior in refractory MM, leading to better management of those patients with the development of new treatment strategies.

Prof. Dr. Hideto Tamura
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)